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Abstract
Background: One of the main obstacles for successful cancer polychemotherapy is multiple drug resistance 
phenotype (MDR) acquired by tumor cells. Currently, RNA interference represents a perspective strategy to overcome 
MDR via silencing the genes involved in development of this deleterious phenotype (genes of ABC transporters, 
antiapoptotic genes, etc.).
Methods: In this study, we used the siRNAs targeted to mdr1b, mdr1a, and bcl-2 mRNAs to reverse the MDR of tumors 
and increase tumor sensitivity to chemotherapeutics. The therapy consisting in ex vivo or in vivo application of mdr1b/
1a siRNA followed by cyclophosphamide administration was studied in the mice bearing RLS40 lymphosarcoma, 
displaying high resistance to a wide range of cytostatics.
Results: Our data show that a single application of mdr1b/1a siRNA followed by treatment with conventionally used 
cytostatics results in more than threefold decrease in tumor size as compared with the control animals receiving only 
cytostatics.
Conclusions: In perspective, mdr1b/1a siRNA may become a well-reasoned adjuvant tool in the therapy of MDR 
malignancies.
Background
A substantial progress in the study of cancer develop-
ment was achieved during last decades. However, mortal-
ity from these diseases still remains high despite the
appearance of new highly efficient therapeutics and new
polychemotherapy programs. One of the main obstacles
for successful polychemotherapy of cancer diseases is the
development of multiple drug resistance (MDR) pheno-
type, the resistance to a wide range of chemotherapeutic
agents, acquired by cancer cells [1].
The primary cause of MDR phenotype is attributed to
an overexpression of some members of a highly con-
served gene family (from bacteria and barley to man) of
transmembrane ATP-binding cassette proteins, referred
to as the ABC transporters superfamily [2-4]. The human
MDR1 (ABCB1) gene and two mouse genes, mdr1b and
mdr1a (Abcb1b and Abcb1a), that belong to subfamily B
of ABC-transporters encode P-glycoprotein (Pgp),
involved in active ATP-dependent transport of cytotoxic
agents out of the cells [5-7]. Being a complex process,
MDR arises also from the expression abnormalities of
other genes, namely, the genes encoding pro- and anti-
apoptotic factors p53, Bax, Bad, and Bcl-2 [5-10]; genes of
the glutathione pathway [2,4]; and genes encoding topoi-
somerases [3,4,11]. However, the most frequent cause of
the MDR phenotype development in many human and
rodent tumors is an increased level of Pgp [12-14]. One of
the strategies to overcome MDR is to increase the intrac-
ellular concentration of chemotherapeutics using P-gly-
coprotein inhibitors [15]. Another strategy is to silence
the genes involved in MDR using small interfering RNA
(siRNA), which seems to be a promising tool.
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In our previous work [16], RLS40 cell line, exhibiting
MDR, was obtained by cultivation of murine ascitic lym-
phosarcoma RLS cells, resistant to apoptosis-inducing
agents, in the presence of vinblastine. The MDR of RLS40
cells was provided by a high expression of mdr1b and
mdr1a  genes and a moderate expression of bcl-2  and
appeared as a 20-fold decrease in the cell sensitivity to a
wide range of cytostatics (cyclophosphamide, cysplatin,
vinblastine, and rubomycin) [16]. The obtained RLS40 cell
line generates tumors in mice and mimics the tumor sta-
tus observed in patients after several chemotherapy
courses [17]. Thus, we had at our disposal two lym-
phosarcoma models displaying MDR: the MDR of RLS40
is mdr1b/1a-associated and the MDR of RLS tumor is
predominantly bcl-2-associated.
In this study, we applied the mdr1b/1a siRNA targeted
to mdr1b and mdr1a mRNAs and bcl-2 siRNA addressed
to bcl-2 mRNA aiming to reverse the MDR phenotype of
tumor cells and increase their sensitivity to chemothera-
peutics. The potential of siRNAs was studied in vitro: we
showed that mdr1b/1a and bcl-2 siRNAs caused five- and
two-fold decrease in the corresponding mRNA levels,
respectively, and mdr1b/1a siRNA exerted an increase in
cell sensitivity to cytostatics. The application of siRNA
followed by cyclophosphamide administration was stud-
ied ex vivo and in vivo using RLS40 and the related RLS
lymphosarcomas developed in mice. Our data showed
that single application of mdr1b/1a siRNA and cyclo-
phosphamide resulted in a decrease in the MDR and a
threefold decrease in the tumor size as compared with
the control animals treated only with cyclophosphamide,
while bcl-2 siRNA was ineffective in vivo.
Methods
Mice
Male 10-12 week-old CBA/LacSto (hereinafter, CBA)
mice obtained from the animal breeding facility with the
Institute of Cytology and Genetics (Siberian Branch, Rus-
sian Academy of Sciences, Novosibirsk, Russia) were
used in this study. All animal procedures were carried out
in accordance with approved protocol and recommenda-
tions for proper use and care of laboratory animals [Euro-
pean Communities Council Directive 86/609/CEE].
Tumor generation
Ascites RLS and RLS40 lymphosarcomas are permanent
and maintained in CBA mice by regular passaging of
tumor cells. For generating ascites tumors, 2 × 105 tumor
cells in 0.2 ml of buffered saline were intraperitoneally
injected into the abdominal cavities of CBA mice. For
generating solid tumors, intramuscular injections of 2 ×
105 tumor cells in 0.1 ml of solution were made into the
right lower limbs of CBA mice.
Isolation of primary tumor culture from ascites
On days 10-12 of RLS or RLS40 tumor development, 0.5
ml of phosphate buffered saline (PBS) was injected into
the abdominal cavity. Then mice were sacrificed by cervi-
cal dislocation to collect the ascites fluid with syringe. To
eliminate the erythrocytes, the collected cell suspension
was diluted with 5 ml of PBS, layered over 3 ml of LSM
(lymphocyte separation medium, MP Biomedicals,
United States), and centrifuged at 1500 rpm for 15 min.
The tumor cells, localized to the mononuclear fraction,
were collected, washed with PBS, and centrifuged at 1000
rpm for 5 min. The collected cells were suspended in the
Iscove's Modified Dulbecco's Medium (IMDM) supple-
mented with 10% fetal bovine serum (FBS), 1% antibiotic
antimycotic solution (10 000 μg/ml streptomycin, 10 000
IU/ml penicillin, and 25 μg/ml amphotericin; ICN, Ger-
many). The cells were cultivated at 37°C in a humidified
incubator with 5% CO2 until a complete adhesion of mac-
rophages to the flask bottom. Then the cell suspension
containing lymphocytes was transferred to a new flask
and cultivated under the same conditions. In the in vitro
experiments on analysis of siRNA silencing activity and
sensitivity of siRNA-treated tumor cells to cytostatics,
the cells were cultivated not more than 1 month. To per-
form ex vivo experiments, the isolated cells were inocu-
lated in mice immediately after transfection with the
corresponding siRNA.
Design of siRNAs
The sequence for mdr1b/1a siRNA was selected using the
data from GenBank [GenBank: M14757]; the sequence
for bcl-2 siRNA was chosen according to Wacheck et al.
[18]. The siRNAs had the following sequences: mdr1b/1a
siRNA, sense 5'-GGCUGGACAAGCUGUGCAUGG-3'
and antisense 5'-AUGCACAGCUUGUCCAGCCAA-3'
and bcl-2 siRNA, sense 5'-GCCUUUGUGGAAC-
UAUAUGGdTdT-3' and antisense 5'-CCAUAUAGUUC-
CACAAAGGCdTdT-3'; luciferase siRNA was used as a
control (sense 5'-CGUUAUUUAUCGGAGUUGCAG-3'
and antisense 5'-GCAACUCCGAUAAAUAACGCG-3')
[19]. The siRNAs were chemically synthesized at the Lab-
oratory of RNA Chemistry (Institute of Chemical Biology
and Fundamental Medicine).
Duplex formation of siRNAs
The sense and antisense strands of siRNAs at a concen-
tration of 20 μM were incubated in annealing buffer (100
mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and
2 mM magnesium acetate) at 90°C for 1 min and then at
37°C for 1 h. The formed duplexes were kept at -20°C.
Cell transfection with siRNAs
Tumor cells were placed in a serum-free medium into six-
well plates immediately before transfection. The cellsPatutina et al. BMC Cancer 2010, 10:204
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were incubated with siRNA precomplexed with Lipo-
fectamine™ 2000 (Invitrogen, United States) in an Opti-
MEM medium (Invitrogen, United States) at 37°C for 4 h
according to the manufacturer's protocol. Then the
medium was replaced with a supplemental medium con-
taining 10% FBS, and the cells were cultivated for 24-96 h
under standard conditions. In the ex vivo experiments,
the cells after transfection were twice washed with PBS
and diluted with PBS to a concentration of 2 × 106 cells/
ml.
RNA isolation
Total RNA was isolated from cells according to published
protocol [20]. RNA concentration in the samples was
measured by absorbance at 260 and 280 nm using a Bio-
Mate 3 (Thermo Electron Corporation) spectrophotome-
ter.
Semiquantitative RT-PCR analysis
The primers and RT-PCR conditions were earlier
described in detail [16]. β-Actin product was used as an
internal control. Amplification was performed in the fol-
lowing mode: the initial step at 95°C for 5 min; 24, 25, and
30 cycles at 94°C for 1 min, 57°C for 1 min, and 72°C for 1
min for mdr1b, mdr1a, and bcl-2, respectively; and the
final elongation step at 72°C for 5 min. The PCR products
were analyzed by 8% PAGE, visualized with ethidium
bromide staining, photographed in UV light, and densito-
metrically quantified using a Gel-Pro Analyzer 4.0. The
data were presented as the ratio of specific gene expres-
sion level to β-actin expression level.
Cell viability in the presence of cytostatics (MTT test)
The change in sensitivity of RLS40 cells to vinblastine after
transfection with siRNA was tested by MTT assay [21].
Vinblastine (Sigma, United States) was added to cells at
concentrations of 10 to 700 nM 48 h after transfection,
and the cells were incubated at 37°C for 48 h in a humidi-
fied incubator with 5% CO2. Then MTT solution was
added to cells at a final concentration of 0.5 mg/ml, and
the cells were incubated for 3-4 h under the same condi-
tions. The medium was removed; the crystallized forma-
zan was dissolved in 100 μl of DMSO; and optical density
was measured at a wavelength of 570 nm (background, at
620 nm) in a Multiscan RS (TermoLabsystems) multi-
channel spectrophotometer.
Rhodamine 123 efflux assay
The intracellular accumulation of the substrate of Pgp,
Rhodamine 123 (Rh123), was measured to evaluate the
Pgp activity in RLS40  cells after the transfection with
mdr1b/1a siRNA according to [22]. Cells (5 × 105) were
washed with PBS, resuspended in 0.5 ml of serum-free
IMDM, and incubated with 10 μM of the Pgp inhibitor
Verapamil for 45 min at 37°C and 5% CO2. To determine
the influx, Rh123 was added to cells to a final concentra-
tion of 5 μM. The cells were incubated for 15 min at 37°C
and 5% CO2 in the darkness. After the influx step, the
cells were washed with serum-free medium, resuspended
in 0.5 ml of this medium, and cultivated for 3 h at 37°C
and 5% CO2 to determine the efflux. Rh123 efflux was
stopped by cooling the cells at 4°C, and the cells were
washed with ice-cold PBS. Propidium iodide was added
to the cells for assessing viability. The analysis was per-
formed in a Cytomics FC 500 (Beckman Coulter) flow
cytometer by accumulating events in the FL1 channel.
The median fluorescence (ΔF) of samples was used to
calculate the percentage of Rh123 intracellular accumula-
tion (A%):
where ΔFVer is a median fluorescence of the cells incu-
bated with Rh123 and Verapamil; ΔFmdr1b/1a siRNA, a
median fluorescence of the cells transfected with mdr1b/
1a siRNA and incubated with Rh123; and ΔFluc siRNA, a
median fluorescence of the cells transfected with
luciferase siRNA and incubated with Rh123.
Tumor development in the presence of siRNA and/or 
cytostatics
Ex vivo. RLS40 or RLS ascites were taken from CBA mice.
The RLS40 cells isolated from ascites fluid by filtration
through LSM were divided into four portions: (1) wild-
type cells (hereinafter, wt cells), (2) the cells transfected
with control luciferase siRNA, (3) the cells transfected
with mdr1b/1a siRNA at a concentration of 100 nM, and
(4) the cells transfected with bcl-2 siRNA at a concentra-
tion of 200 nM. The RLS cells isolated from ascites fluid
were divided into three portions: (1) wt cells; (2) the cells
transfected with control luciferase siRNA; and (3) the
cells transfected with bcl-2 siRNA at a concentration of
200 nM. The cell suspensions (0.1 ml, 2 × 106 cells/ml) 4 h
after transfection were intramuscularly inoculated into
the right lower limb of 14-16-week-old male CBA mice
for solid tumor development. On days 2 and 4 after tumor
cell inoculation, a half of the RLS40-bearing animals from
each group was intraperitoneally injected with 100 mg/kg
of cyclophosphamide (Biokhimik, Saransk, Russia) or
with 1.5 mg/kg of vinblastine and a half of RLS-bearing
animals from each group was once intraperitoneally
injected with 200 mg/kg of cyclophosphamide on day 2
after transplantation. The other half of each group was
injected with buffered saline. Each group included 40
mice.
In vivo. The CBA mice with generated RLS40 ascites
tumors were divided into two groups: the mice were
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intraperitoneally injected with (1) 15 μg of control
luciferase siRNA or (2) 15 μg of mdr1b/1a siRNA. Prior
to injection, the siRNAs were precomplexed with Lipo-
fectamine in Opti-MEM medium. The ascites 4 h after
injection were collected from each group of animals,
diluted with PBS to a concentration of 2 × 106 cells/ml,
and 0.1 ml of this suspension was intramuscularly inocu-
lated into the right lower limb of 14-16-week-old male
mice for solid tumor development. On day 2 after tumor
inoculation, each group of animals was divided into three
subgroups (20 mice per subgroup): subgroup 1 was intra-
peritoneally injected with 200 mg/kg of cyclophosph-
amide; subgroup 2 intravenously injected with 2 mg/kg of
embichin (mechlorethamine hydrochloride, Aldrich,
United States); and subgroup 3 (control subgroup) was
injected with buffered saline.
As soon as tumors began to be palpable, the tumor vol-
umes were measured every 2-3 days using calipers. When
the experiment was finished, the animals were sacrificed
by cervical dislocation. Tumor weight was determined as
the difference between the weights of the amputated
tumor-bearing stump and the tumor-free contralateral
stump. The inhibition of tumor growth was estimated as
follows: [mean tumor weightcontrol - mean tumor weightex-
periment]/mean tumor weightcontrol. The liver was weighed
for hepatic index calculation. Hepatic index was esti-
mated as follows: (liver weight/mouse weight) × 100%.
The liver index of healthy CBA mice was 5.0%.
Statistics
The data were statistically processed using the Student's
t-test (two-tailed, unpaired); p < 0.05 was considered sta-
tistically significant.
Results
Design of siRNAs
To reverse the MDR phenotype of tumor cells, we applied
in our experiments two siRNAs: the bcl-2 siRNA targeted
to  bcl-2  mRNA and the mdr1b/1a siRNA targeted to
mdr1b  and  mdr1a mRNAs. The mdr1b/1a siRNA was
designed to target mdr1b and mdr1a genes simultane-
ously. The sequence of mdr1b/1a siRNA antisense strand
is complementary to the mdr1b  mRNA and is able to
form a duplex with three mismatches with mdr1a mRNA.
Note that the mismatches are located at the 5'-end of the
antisense strand, which makes this strand favorable for
RISC loading [23]. It has been shown earlier that an effi-
cient silencing of c-myc and N-myc genes is feasible using
single siRNA [24]. The sequences of mdr1b and mdr1a
mRNAs for targeting with mdr1b/1a siRNA were chosen
based on the results of the studies [25,26] where the siR-
NAs addressed to various regions of MDR1 mRNA were
screened: the designed siRNAs displayed silencing activ-
ity and no off-target effects.
In vitro
The siRNAs targeted to the mRNA of mdr1b, mdr1a and
bcl-2 genes were tested for their ability to downregulate
the synthesis of Pgp and Bcl-2 proteins in the RLS40 cell
line, displaying MDR phenotype. The siRNA targeted to
the mRNA of firefly luciferase gene was used as a control.
RLS40 cells were transfected with specific siRNA at con-
centrations of 20 to 200 nM in the presence of Lipo-
fectamine and 24-96 h post transfection, the expression
levels of mdr1a, mdr1b, and bcl-2 genes were measured
by semiquantitative RT-PCR.
According to the kinetics of the gene silencing by spe-
cific siRNAs, the minimal levels of mdr1a, mdr1b, and
bcl-2 mRNAs in RLS40 cell line were detected 48 h after
transfection (primary data not shown). At that time
point, the bcl-2 and mdr1b/1a siRNAs caused a twofold,
fivefold and fourfold reduction in the level of the bcl-2,
mdr1b and mdr1a mRNAs, respectively (Figure 1A, B).
However, 96 h after transfection, the levels of mRNAs
restored. Analysis of the concentration dependences of
gene silencing demonstrated that the bcl-2 and mdr1b/1a
siRNAs at a concentration of 200 nM caused a maximal
decrease in bcl-2 and mdr1b mRNA levels (Figure 1A, B).
A further increase in mdr1b/1a siRNA concentration up
to 200 nM failed to additionally decrease the mdr1a
mRNA level: the observed change in mRNA levels was
within the experimental error.
The  mdr1a  and  mdr1b  genes of mice encode Pgp,
which exports chemotherapeutic agents out of cancer
cells, thereby providing for a decrease in drug accumula-
tion in tumors. The silencing effect of mdr1b/1a siRNA
on mdr1a and mdr1b genes should be accompanied by a
decrease in Pgp activity; therefore, we studied the effect
of mdr1b/1a siRNA on the Pgp pump function. Rh123 is a
well-known substrate for Pgp efflux and is commonly
used for the measurement of Pgp bioactivity. In the
Rh123 efflux assay, the Pgp activity was blocked by a
commonly used Pgp inhibitor, Verapamil (as a positive
control). Thus, the efficacy of mdr1b/1a siRNA was eval-
uated relative to the inhibitory effect of Verapamil. Accu-
mulation of Rh123 in the tumor cells cultivated with
Verapamil was considered 100%. As expected according
to the Rh123 efflux assay, tumor cells intensively pumped
out Rh123 in the absence of inhibitors of Pgp activity. The
control luciferase siRNA did not influence the Pgp activ-
ity (Figure 2A), and Rh123 cellular accumulation was low
(regarded as 0%), whereas the efflux of fluorescent dye
was considerably decreased in the RLS40 cells transfected
with mdr1b/1a siRNA (Figure 2A, B). The highest level of
Rh123 accumulation was observed 48 and 72 h after
transfection with 100 and 200 nM of mdr1b/1a siRNA:
the Rh123 accumulation reached 38 and 62%, respec-
tively, as compared with the cells transfected with control
siRNA (Figure 2B).Patutina et al. BMC Cancer 2010, 10:204
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Figure 1 Silencing of mdr1b, mdr1a, and bcl-2 genes in RLS40 cells by siRNAs. (A) RT-PCR analysis (8% PAGE) of mdr1b, bcl-2, and mdr1a mRNA 
levels in the RLS40 cells transfected with control luciferase siRNA, mdr1b/1a siRNA, and bcl-2 siRNA (20-200 nM) 48 h after transfection. (B) Dose de-
pendence of the silencing effect of gene-specific siRNAs on bcl-2, mdr1a, and mdr1b genes in RLS40 cells 48 h after transfection according to semi-
quantitative RT-PCR assay. The expression levels of mdr1b, mdr1a, and bcl-2 genes in the tumor cells transfected with luciferase siRNA (specific gene 
product/β-actin = 100%) were used as controls.
Figure 2 The levels of Pgp activity in the RLS40 cells treated with siRNA according to Rh123 efflux assay. (A) Flow cytometry data showing the 
inhibitory effect of Verapamil and specific mdr1b/1a siRNA (200 nM, 48 h after transfection). (B) Dose and time dependences of the Rh123 accumula-
tion in RLS40 cells mediated by mdr1b and mdr1a gene silencing induced by mdr1b/1a siRNA. The plots show the data of three independent experi-
ments.Patutina et al. BMC Cancer 2010, 10:204
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The downregulation of mdr1a and mdr1b gene expres-
sion by specific siRNA resulted in a decrease in the Pgp
quantity in the cytoplasmic membrane, which contrib-
utes to accumulation of cytostatics in the cytoplasm lead-
ing to cell death. The sensitivity of RLS40  cells to
vinblastine was evaluated 48 h after transfection with
mdr1b/1a siRNA, when the levels of mdr1a and mdr1b
mRNAs were the lowest. The IC50 of vinblastine (concen-
tration of vinblastine at which 50% of the cells remained
viable) for the RLS40  cells transfected with luciferase
siRNA was 691.4 ± 44.2 nM, being similar to the IC50 for
untransfected RLS40 cells. The transfection of RLS40 cells
w i t h  m d r 1 b / 1 a  s i R N A  r e s u l t e d  i n  a n  u p  t o  t h r e e f o l d
increase in the cell sensitivity to vinblastine (Figure 3): the
IC50 of vinblastine was 315.4 ± 25.1, 278.3 ± 23.1, and
235.5 ± 20.1 nM for the cells transfected with 20, 50, and
100 nM of mdr1b/1a siRNA, respectively. Note that for
the parental RLS cell line, which is more susceptible to
chemotherapy, the IC50 value for vinblastine was 6.2 nM.
Ex vivo
The ability of mdr1b/1a and bcl-2 siRNAs to overcome
the MDR phenotype was tested in ex vivo experiments.
The ascites of RLS40 or RLS tumors were collected; the
c e l l s  w e r e  i s o l a t e d  a n d  t r a n s f e c t e d  w i t h  s i R N A s  a s
described in Materials and Methods. Then tumor cells
were inoculated into the right thigh muscle of mice for
solid tumor development. In the experiment with RLS40
tumor, the mice were twice treated with cyclophosph-
amide (100 mg/kg), on days 2 and 4 after transplantation;
in the experiment with parental RLS tumor, the mice
were once treated with cyclophosphamide (200 mg/kg)
on day 2 after transplantation. After transfection, approx-
imately 5 × 105 cells from each sample were left and incu-
bated at 37°C and 5% CO2 for 48 h. Then the cells were
used for measuring of mdr1a, mdr1b, and bcl-2 mRNA
levels. RT-PCR analysis demonstrated that mdr1b/1a
siRNA caused a fourfold downregulation of expression of
mdr1a and mdr1b mRNAs and bcl-2 siRNA - a twofold
downregulation of expression of bcl-2 gene as compared
with the wt cells and luciferase siRNA-treated cells.
The dynamics of tumor growth is shown in Figure 4.
The growth rates of the RLS40 tumors either wt or trans-
fected with luciferase or mdr1b/1a siRNA were similar
(Figure 4A, black curves), while cyclophosphamide
administration resulted in a twofold retardation of tumor
growth in the mice with wt RLS40 tumors and mice bear-
ing the tumors transfected with luciferase siRNA (Figure
4A, blue curves), thus showing the absence of specific
effect of the control siRNA on the tumor growth. The
administration of cyclophosphamide in the case of the
RLS40 cells transfected with mdr1b/1a siRNA resulted in
a twofold retardation of tumor growth as compared with
only cyclophosphamide action and sixfold, as compared
with the untreated tumors (Figure 4A, red curve). The
treatment of RLS40 cells with the bcl-2 siRNA followed by
cyclophosphamide administration had no effect on the
RLS40 tumor growth (data not shown), which is explain-
able by a major contribution of mdr1a and mdr1b gene
products to MDR development (Pgp-mediated MDR
phenotype) as compared with bcl-2 gene.
The block of apoptosis is a distinctive feature of the
parental RLS tumor: a sixfold increase in the expression
level of bcl-2 mRNA was observed for the parental RLS
lymphosarcoma as compared with RLS40 tumor. There-
fore, an antitumor potential of bcl-2 siRNA and cyclo-
phosphamide was examined ex vivo using the RLS
lymphosarcoma. Analysis of dynamics of RLS tumor
growth failed to find any significant difference between
the growth rates of wt tumor, the tumor transfected with
control luciferase siRNA, and specific bcl-2 siRNA after
cyclophosphamide impact (Figure 4B).
The ability of mdr1b/1a siRNA to sensitize RLS40 tumor
to cytostatics was also studied in an ex vivo experiment
using vinblastine. The dynamics of tumor growth showed
that the double treatment including mdr1b/1a siRNA and
vinblastine had no effect on tumor progress (data not
shown). The reason could be a high resistance of RLS40
tumor cells to this particular cytostatic (IC50 = 680 ± 42
nM): the tolerable dose of vinblastine administered to
animals was lower than the IC50 values observed in vitro
even after silencing of mdr1b gene with the correspond-
ing siRNA (283 ± 4 nM).
Figure 3 The sensitivity of RLS40 cells to vinblastine. The viability of 
RLS40 cells transfected with control luciferase siRNA (100 nM) or 
mdr1b/1a siRNA (100 nM) was measured by MTT-test 48 h after incu-
bation with vinblastine.Patutina et al. BMC Cancer 2010, 10:204
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In all groups of mice, the hepatic index (HI), an indica-
tor of animal health, was measured. The HI in healthy
CBA mice is 5.0%. In the groups of the RLS40-bearing ani-
mals treated with cyclophosphamide only or cyclophos-
phamide following the transfection with the luciferase
siRNA, the HI was 8.6 ± 0.6%. The HI was 6.1 ± 0.9% in
the mice bearing RLS40 tumors treated with cyclophosph-
amide after mdr1b/1a siRNA transfection. An average
lifetime for mice of this group was 25 ± 1.8 days versus
21.4 ± 1.5 days in the groups treated with cyclophosph-
amide only or cyclophosphamide with the control siRNA.
In vivo
The efficacy of cytostatic treatment following the silenc-
ing of mdr1b and mdr1a genes with siRNA was tested in
vivo. RLS40 ascites tumors were transfected in vivo with
(1) luciferase siRNA or (2) mdr1b/1a siRNA. The RLS40
ascites were extracted 4 h post transfection, and the cells
were intramuscularly transplanted into new groups of
mice for solid tumor formation. After transfection,
approximately 106 cells were isolated from the ascites
fluid and incubated at 37°C and 5% CO2 for 48 h. Then
the cells were used for measuring the mdr1a and mdr1b
m R N A  l e v e l s .  R T - P C R  a n a l y s i s  d e m o n s t r a t e d  t h a t  t h e
mdr1b/1a siRNA caused a fourfold downregulation of
expression of mdr1a and mdr1b genes as compared with
the luciferase siRNA-treated cells (Figure 5).
On day 2 of tumor development, the mice were treated
with embichin (2 mg/kg) or cyclophosphamide (200 mg/
kg). Analysis of the tumor growth dynamics showed that
the tumors derived from the cells transfected with
mdr1b/1a siRNA were more sensitive to chemotherapy as
compared with the cells transfected with the control
siRNA (Figure 4C). Both cytostatics, embichin and cyclo-
phosphamide, caused a significant retardation of tumor
growth only in the mice treated with mdr1b/1a siRNA:
the tumors were 1.4-fold smaller in the case of embichin
(Figure 4C, orange curve) and 3.3-fold smaller in the case
of cyclophosphamide (Figure 4C, red curve) as compared
with the corresponding control groups. On the other
hand, administration of embichin only did not influence
the tumor growth in the control group (the tumors trans-
fected with luciferase siRNA) (Figure 4C, black curve,
diamond points). Cyclophosphamide had a more pro-
nounced effect on the tumor growth: the tumors trans-
fected with luciferase siRNA were twofold smaller (Figure
4C, black curve, triangle points) than the tumors without
treatment. The HI in the group received luciferase siRNA
and cyclophosphamide was 9.2 ± 0.7% versus 7.7 ± 0.8%
in the group received mdr1b/1a siRNA. An average life-
time for the mice of this group was 20.6 ± 0.7 days versus
Figure 4 The dynamics of tumor development in mice after ex vivo and in vivo successive treatment with siRNA and cytostatics. (A) RLS40-
bearing animals: wt, control mice bearing wild type tumor; luc siRNA, the mice bearing tumor cells transfected ex vivo with control luciferase siRNA; 
and mdr1b/1a siRNA, the mice bearing tumor cells transfected ex vivo with mdr1b/1a siRNA; (+CP) the animals treated with cyclophosphamide (100 
mg/kg) on days 2 and 4 after tumor transplantation and (-CP) the animals without chemotherapeutic treatment. (B) RLS-bearing animals: wt, the con-
trol animals bearing wild type tumor; luc siRNA, the mice bearing tumor cells transfected ex vivo with control luciferase siRNA; and bcl-2 siRNA, the 
mice bearing tumor cells transfected ex vivo with bcl-2 siRNA; (+CP) the animals treated with cyclophosphamide (200 mg/kg) on day 2 after tumor 
transplantation and (-CP) the animals without chemotherapeutic treatment. (C) RLS40-bearing animals: luc siRNA, the mice with tumors transfected 
in vivo with luciferase siRNA and mdr1b/1a siRNA, the mice with tumors transfected in vivo with mdr1b/1a siRNA; (-) the animals without chemother-
apeutic treatment, (+E) the animals treated with embichin (2 mg/kg) or (+CP) cyclophosphamide (200 mg/kg) on day 2 after tumor transplantation. 
** p < 0.01, compared with cytostatic treatment; ## and ###, p < 0.01 and p < 0.001, respectively, compared with wt (A) or -/luc siRNA and -/mdr1b/
1a siRNA (C).Patutina et al. BMC Cancer 2010, 10:204
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16.8 ± 0.5 days in the group treated with cyclophosph-
amide only or cyclophosphamide with the control siRNA.
Discussion
The range of siRNA application continues to expand.
Researchers attempt to explore the potential of RNA
interference (RNAi) technology for the therapy of com-
municable, autoimmune, cancer, and inflammatory dis-
eases; neural disorders; chronic pains; adiposis; and
insulin-independent diabetes [27-34]. The potential of
siRNA strategy to overcome multidrug resistance in vitro
was demonstrated in a number of studies [25,26,35-39],
and the success in in vivo experiments is retarded by
unsettled challenges in the in vivo siRNA delivery tech-
nologies [40,41].
Development of MDR to a variety of conventional and
novel chemotherapeutic agents is a significant obstacle in
effective therapy of refractory cancer types. In our previ-
ous work, we established two murine lymphosarcoma
models with a stable MDR, namely, RLS and RLS40 [16].
These two related tumors differed in the origin of drug
resistance: the MDR of RLS40 tumor is mdr1a/mdr1b-
associated and the MDR of RLS tumor is bcl-2-associ-
ated. These lymphosarcomas are the allografts, exhibiting
the adequate response of the body.
In this work, we applied the siRNA targeted to the
mRNAs of bcl-2, mdr1b, and mdr1a genes to overcome
the MDR phenotype of lymphosarcomas RLS40 and RLS.
It was shown that mdr1b/1a siRNA caused the decrease
in both mdr1b and mdr1a mRNA levels. Although the
mdr1b/1a siRNA has three mismatches in the binding
site of mdr1a mRNA, we believe that this siRNA does not
provide a miRNA effect and acts via the RNA interfer-
ence mechanism. The key features that distinguish a
miRNA from a siRNA are (1) a noncomplementarity
between the center on the miRNA and the targeted
mRNA [42,43] and (2) a decrease in the protein level
rather than the mRNA level [44]. In our case, we
observed a concentration-dependent reduction in the
mdr1a mRNA level after treating the cells with mdr1b/1a
siRNA. The mismatches between mdr1b/1a siRNA and
mdr1a mRNA are localized to the 5'-end of the siRNA
antisense strand rather than to its central part. Therefore,
the total effect of MDR reversing is provided by the deg-
radation of both mdr1b and mdr1a mRNAs via an RNA-
interference pathway.
The effect of mdr1b/1a siRNA resulted in a substantial
increase in the sensitivity of cancer cells to chemothera-
peutics both in vitro and in vivo and led to a threefold
retardation of tumor growth upon cyclophosphamide
administration. Interestingly, we observed a more effi-
cient inhibition of tumor growth in in vivo experiment as
compared with ex vivo experiment. It could be explained
by the difference in the treatment schemes, namely, a
Figure 5 Silencing of mdr1b and mdr1a genes in lymphosarcoma RLS40 by siRNAs. RT-PCR analysis (8% PAGE) of mdr1b mRNA level (A) and 
mdr1a mRNA level (B) 48 h after transfection of RLS40 ascites with 15 μg of luciferase or mdr1b/1a siRNA in vivo. (C) The expression levels of mdr1b and 
mdr1a genes in the tumor cells transfected with mdr1b/1a siRNA. The expression levels of mdr1b and mdr1a genes in the wild-type tumor cells and 
cells transfected with luc siRNA were used as controls.Patutina et al. BMC Cancer 2010, 10:204
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double administration of cyclophosphamide on days 2
and 4 after tumor implantation at a dose of 100 mg/kg in
the  ex vivo experiment and a single administration of
cyclophosphamide on day 2 at a doubled dose in the in
vivo experiment.
Our data demonstrated that the mdr1b/1a siRNA in
vivo  sensitized RLS40 tumor cells to cyclophosphamide
and embichin. Cyclophosphamide itself is not cytotoxic
but undergoes metabolic changes in the body predomi-
nantly in the liver with the formation of an active deriva-
tive, phosphoramide mustard [45], which is an alkylating
agent capable of forming cross-links in DNA molecules
and initiating apoptosis. Phosphoramide mustard has not
been regarded as a substrate of Pgp [46]. The observed
inhibition of RLS40 tumor growth after an ex vivo treat-
ment of tumor cells with mdr1b/1a siRNA followed by in
vivo  administration of cyclophosphamide suggests that
this toxic agent is yet a substrate of Pgp. To confirm this
assumption in in vivo experiment, mice were injected
with embichin (nitrogen mustard), another active alkylat-
ing agent with similar cytotoxic properties. Although
embichin was not as efficient as cyclophosphamide, the
obtained results supported this hypothesis.
Our data showed that bcl-2 siRNA specifically down-
regulated the bcl-2 mRNA level by 50% in vitro; however,
the bcl-2 siRNA in vivo neither showed any sensitizing
effect on RLS tumor nor influenced the tumor growth. In
addition to the classical Pgp-based mechanism of multi-
drug resistance of cancer cells [47-50], there is an alterna-
tive mechanism associated with putative effector
pathways of drug action, apoptosis, and senescence [51-
59]. It was shown that Pgp could modulate caspase acti-
vation, e.g., caspase 8, and inhibit apoptosis [60]. Thus,
the Pgp inhibitors, which reverse drug resistance, can
also block its caspase-inhibitory function [60]. Although
an MDR phenotype of RLS is considered as bcl-2-associ-
ated, the expression levels of mdr1a and mdr1b genes in
these cells are also rather high [16]. In both RLS and
RLS40 cells, high levels of Pgp and Bcl-2 resulted in a
"double" suppression of apoptosis. The mdr1b/1a siRNA-
induced decrease in the Pgp level resulted in triggering of
proapoptosis, while the decrease in Bcl-2 caused by bcl-2
siRNA is not sufficient to overcome the MDR of tumor
due to a high Pgp level. Another possible reason for the
absence of tumor sensitivity to cyclophosphamide after
bcl-2 siRNA transfection is that a 50% downregulation of
bcl-2 mRNA expression can be insufficient.
The results demonstrating the sensitizing properties of
mdr1b/1a siRNA cannot be immediately applied in the
clinical practice; however, it is really encouraging that
even a single administration of siRNA resulted in essen-
tial tumor growth retardation and increase in the average
lifetime by approximately 20%. Thus, the examined ther-
apy has significant promise in the clinical management of
refractory cancer diseases.
Conclusions
In view of our results, the synthetic siRNA targeted to
mdr1b and mdr1a genes overcame MDR phenotype in
vivo and, in the successive treatment with conventionally
used cytostatics, evoked more than threefold increase in
the tumor cell sensitivity to chemotherapy after a single
siRNA administration. In clinical practice, a twofold
decrease in the cancer cell resistance to chemotherapy is
sufficient to achieve a significant enhancement in the effi-
ciency of antitumor therapy.
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